Newcastle University

Prolysis Ltd, the UK leading antibiotic discovery and development company, has been acquired by a major Australian Biotech company, Biota.

Prolysis was founded in 1998 by Prof Jeff Errington, whilst he was working in Oxford. Biota have been major players in the antiviral drug market and developed, for example, the anti-flu compound Relenza, which has generated large cash flows in recent months. Biota see the acquisition of Prolysis as an opportunity to expand their portfolio across the anti-infectives arena. It will also provide the company with an important base in the northern hemisphere.

Jeff has remained associated with Prolysis as a Director, CSO and consultant since the company’s inception. As part of the transaction he has been offered a place on the Board of the parent company in Melbourne.

http://www.biota.com.au/uploaded/154/1021586_49biotaacquirestheantibac.pdf